Sudipa Sarkar1, Todd T Brown2. 1. Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Asthma and Allergy Center 3B.74D, Baltimore, MD, 21224, USA. ssarka19@jhmi.edu. 2. Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333, Baltimore, MD, 21287, USA.
Abstract
PURPOSE OF REVIEW: To discuss the diagnosis, treatment, and complications of diabetes in people with HIV (PWH) and to review HIV-related factors that may contribute to the development of diabetes or alter decisions in the care and treatment of PWH with diabetes. RECENT FINDINGS: For those patients with atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, GLP-1 receptor agonists and SGLT-2 inhibitors should be considered for use. Evidence for this recommendation is, however, based on studies that were not conducted in populations consisting solely of PWH. Diabetes is a significant comorbidity in PWH and adds to their already heightened risk of cardiovascular disease. HIV-specific factors, including interactions of antiretroviral therapy with medications that either treat diabetes and/or prevent cardiovascular disease, should be evaluated.
PURPOSE OF REVIEW: To discuss the diagnosis, treatment, and complications of diabetes in people with HIV (PWH) and to review HIV-related factors that may contribute to the development of diabetes or alter decisions in the care and treatment of PWH with diabetes. RECENT FINDINGS: For those patients with atherosclerotic cardiovascular disease, heart failure, and/or chronic kidney disease, GLP-1 receptor agonists and SGLT-2 inhibitors should be considered for use. Evidence for this recommendation is, however, based on studies that were not conducted in populations consisting solely of PWH. Diabetes is a significant comorbidity in PWH and adds to their already heightened risk of cardiovascular disease. HIV-specific factors, including interactions of antiretroviral therapy with medications that either treat diabetes and/or prevent cardiovascular disease, should be evaluated.
Authors: Steven K Grinspoon; Kathleen V Fitch; Edgar Turner Overton; Carl J Fichtenbaum; Markella V Zanni; Judith A Aberg; Carlos Malvestutto; Michael T Lu; Judith S Currier; Craig A Sponseller; Myron Waclawiw; Beverly Alston-Smith; Katharine Cooper-Arnold; Karin L Klingman; Patrice Desvigne-Nickens; Udo Hoffmann; Heather J Ribaudo; Pamela S Douglas Journal: Am Heart J Date: 2019-03-04 Impact factor: 4.749
Authors: Marco Gelpi; Shoaib Afzal; Andreas Fuchs; Jens Lundgren; Andreas D Knudsen; Ninna Drivsholm; Amanda Mocroft; Anne-Mette Lebech; Birgitte Lindegaard; Jørgen T Kühl; Per E Sigvardsen; Lars Køber; Børge G Nordestgaard; Klaus F Kofoed; Susanne D Nielsen Journal: AIDS Date: 2019-03-15 Impact factor: 4.177
Authors: Niels C Kaarsholm; Songnian Lin; Lin Yan; Theresa Kelly; Margaret van Heek; James Mu; Margaret Wu; Ge Dai; Yan Cui; Yonghua Zhu; Ester Carballo-Jane; Vijay Reddy; Peter Zafian; Pei Huo; Shuai Shi; Valentyn Antochshuk; Aimie Ogawa; Franklin Liu; Sandra C Souza; Wolfgang Seghezzi; Joseph L Duffy; Mark Erion; Ravi P Nargund; David E Kelley Journal: Diabetes Date: 2017-11-02 Impact factor: 9.461
Authors: Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews Journal: N Engl J Med Date: 2017-06-12 Impact factor: 91.245
Authors: Michael P Dubé; Ellen S Chan; Jordan E Lake; Brett Williams; Jennifer Kinslow; Alan Landay; Robert W Coombs; Michelle Floris-Moore; Heather J Ribaudo; Kevin E Yarasheski Journal: Clin Infect Dis Date: 2019-09-13 Impact factor: 20.999
Authors: Julie A Zuñiga; Heather E Cuevas; Kristian Jones; Kristine Adiele; Lauren Cebulske; Livia Frost; Siddhaparna Sannigrahi; Alexandra A García; Elizabeth M Heitkemper Journal: ANS Adv Nurs Sci Date: 2021-12-28 Impact factor: 2.147